

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 July 2024 (25.07.2024)



(10) International Publication Number
WO 2024/153725 A1

(51) International Patent Classification:

A61K 38/20 (2006.01) *C12N 5/0783* (2010.01)
A61K 39/00 (2006.01) *C07K 14/00* (2006.01)
A61P 35/00 (2006.01) *A61K 47/68* (2017.01)
C07K 14/55 (2006.01) *C07K 16/28* (2006.01)
C07K 14/725 (2006.01) *C07K 16/42* (2006.01)
C12N 5/00 (2006.01)

(21) International Application Number:

PCT/EP2024/051096

(22) International Filing Date:

18 January 2024 (18.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23152578.3 20 January 2023 (20.01.2023) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **DAROWSKI, Diana**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **GASSER, Stephan**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **LANG, Simone**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **VENETZ, Dario**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **BUSER, Andres**; F. Hoffmann-La Roche AG, Patent Department, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: RECOMBINANT FC DOMAIN - IL2 VARIANT POLYPEPTIDES AND COMBINATION THERAPY WITH MEMBRANE-ANCHORED ANTIGEN BINDING POLYPEPTIDES

(57) Abstract: The present invention relates to the combination therapy of recombinant Fc domain - IL-2 variant polypeptides with membrane-anchored antigen binding polypeptides in the prevention or treatment of cancer.

WO 2024/153725 A1